Literature DB >> 27815425

STAT6 Regulates the Development of Eosinophilic versus Neutrophilic Asthma in Response to Alternaria alternata.

Andrea C Valladao1,2, Charles W Frevert3, Lisa K Koch2, Daniel J Campbell1,2, Steven F Ziegler4,2.   

Abstract

Human asthma is a heterogeneous disease characterized by the expression of both Th2 and Th17 cytokines. In vitro and in vivo studies have shown a reciprocal regulation between Th2 and Th17 pathways, suggesting a potential induction of neutrophil-promoting Th17 inflammation in the absence of a Th2 response. Alternaria alternata is a clinically relevant allergen that is associated with severe and fatal asthma exacerbations. Exposure to A. alternata is characterized by a predominant Th2 response, but can also induce the production of factors associated with Th17 responses (e.g., CXCL8) from epithelial cells. Using a mouse model, we found that wild-type mice develop an eosinophilic Th2 airway disease in response to A. alternata exposure, whereas IL-4-, IL-13-, and STAT6-deficient mice exhibit a primarily neutrophilic response. Neutrophilic asthma in STAT6-/- mice was accompanied by elevated lung levels of TNF-α, CXCL1, CXCL2, and CXCL5, and was steroid resistant. Neutralization of Th17 signaling only partially reduced neutrophil numbers and total airway inflammation. Airway neutrophilia developed in RAG-deficient and CD4-depleted BALB/c mice, suggesting that the suppression of neutrophil responses is dependent on Th2 cytokine production by T cells and that airway neutrophilia is primarily an innate response to allergen. These results highlight the importance of combination therapies for treatment of asthma and establish a role for factors other than IL-17 as targets for neutrophilic asthma.
Copyright © 2016 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27815425      PMCID: PMC5136320          DOI: 10.4049/jimmunol.1600007

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  55 in total

1.  IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines.

Authors:  S Molet; Q Hamid; F Davoine; E Nutku; R Taha; N Pagé; R Olivenstein; J Elias; J Chakir
Journal:  J Allergy Clin Immunol       Date:  2001-09       Impact factor: 10.793

2.  Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids.

Authors:  S E Wenzel; S J Szefler; D Y Leung; S I Sloan; M D Rex; R J Martin
Journal:  Am J Respir Crit Care Med       Date:  1997-09       Impact factor: 21.405

Review 3.  Monoclonal antibodies for the treatment of asthma.

Authors:  Matthew C Catley; Julie Coote; Mohamed Bari; Kate L Tomlinson
Journal:  Pharmacol Ther       Date:  2011-09-12       Impact factor: 12.310

4.  Induction of glucocorticoid receptor-beta expression in epithelial cells of asthmatic airways by T-helper type 17 cytokines.

Authors:  A Vazquez-Tello; A Semlali; J Chakir; J G Martin; D Y Leung; D H Eidelman; Q Hamid
Journal:  Clin Exp Allergy       Date:  2010-06-09       Impact factor: 5.018

5.  Oral corticosteroids decrease eosinophil and CC chemokine expression but increase neutrophil, IL-8, and IFN-gamma-inducible protein 10 expression in asthmatic airway mucosa.

Authors:  Motonori Fukakusa; Celine Bergeron; Meri K Tulic; Pierre-Olivier Fiset; Oday Al Dewachi; Michel Laviolette; Qutayba Hamid; Jamila Chakir
Journal:  J Allergy Clin Immunol       Date:  2005-02       Impact factor: 10.793

6.  Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.

Authors:  Sally Wenzel; Mario Castro; Jonathan Corren; Jorge Maspero; Lin Wang; Bingzhi Zhang; Gianluca Pirozzi; E Rand Sutherland; Robert R Evans; Vijay N Joish; Laurent Eckert; Neil M H Graham; Neil Stahl; George D Yancopoulos; Mariana Louis-Tisserand; Ariel Teper
Journal:  Lancet       Date:  2016-04-27       Impact factor: 79.321

7.  TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice.

Authors:  Laura McKinley; John F Alcorn; Alanna Peterson; Rachel B Dupont; Shernaaz Kapadia; Alison Logar; Adam Henry; Charles G Irvin; Jon D Piganelli; Anuradha Ray; Jay K Kolls
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

8.  Interleukin-17 is a negative regulator of established allergic asthma.

Authors:  Silvia Schnyder-Candrian; Dieudonnée Togbe; Isabelle Couillin; Isabelle Mercier; Frank Brombacher; Valérie Quesniaux; Francois Fossiez; Bernhard Ryffel; Bruno Schnyder
Journal:  J Exp Med       Date:  2006-11-13       Impact factor: 14.307

9.  Abrogation of bronchial eosinophilic inflammation and airway hyperreactivity in signal transducers and activators of transcription (STAT)6-deficient mice.

Authors:  T Akimoto; F Numata; M Tamura; Y Takata; N Higashida; T Takashi; K Takeda; S Akira
Journal:  J Exp Med       Date:  1998-05-04       Impact factor: 14.307

10.  IL-33 and thymic stromal lymphopoietin mediate immune pathology in response to chronic airborne allergen exposure.

Authors:  Koji Iijima; Takao Kobayashi; Kenichiro Hara; Gail M Kephart; Steven F Ziegler; Andrew N McKenzie; Hirohito Kita
Journal:  J Immunol       Date:  2014-07-11       Impact factor: 5.422

View more
  19 in total

1.  The Innate Immune Protein S100A9 Protects from T-Helper Cell Type 2-mediated Allergic Airway Inflammation.

Authors:  Lauren D Palmer; K Nichole Maloney; Kelli L Boyd; A Kasia Goleniewska; Shinji Toki; C Noel Maxwell; Walter J Chazin; R Stokes Peebles; Dawn C Newcomb; Eric P Skaar
Journal:  Am J Respir Cell Mol Biol       Date:  2019-10       Impact factor: 6.914

Review 2.  Are We Meeting the Promise of Endotypes and Precision Medicine in Asthma?

Authors:  Anuradha Ray; Matthew Camiolo; Anne Fitzpatrick; Marc Gauthier; Sally E Wenzel
Journal:  Physiol Rev       Date:  2020-01-09       Impact factor: 37.312

3.  Eosinophil persistence in vivo and sustained viability ex vivo in response to respiratory challenge with fungal allergens.

Authors:  W E Geslewitz; C M Percopo; H F Rosenberg
Journal:  Clin Exp Allergy       Date:  2017-11-22       Impact factor: 5.018

4.  ADAM10 and Notch1 on murine dendritic cells control the development of type 2 immunity and IgE production.

Authors:  S R Damle; R K Martin; C L Cockburn; J C Lownik; J A Carlyon; A D Smith; D H Conrad
Journal:  Allergy       Date:  2017-08-31       Impact factor: 13.146

5.  Pyruvate kinase M2 in lung APCs regulates Alternaria-induced airway inflammation.

Authors:  Anil Kumar Jaiswal; Sangeet Makhija; Natalie Stahr; Maninder Sandey; Amol Suryawanshi; Amarjit Mishra
Journal:  Immunobiology       Date:  2020-05-30       Impact factor: 3.144

Review 6.  Modeling asthma: Pitfalls, promises, and the road ahead.

Authors:  Helene F Rosenberg; Kirk M Druey
Journal:  J Leukoc Biol       Date:  2018-02-16       Impact factor: 4.962

7.  Emodin alleviates alternatively activated macrophage and asthmatic airway inflammation in a murine asthma model.

Authors:  Yun-Duan Song; Xiao-Zong Li; Ya-Xian Wu; Yao Shen; Fang-Fang Liu; Pei-Pei Gao; Lei Sun; Feng Qian
Journal:  Acta Pharmacol Sin       Date:  2018-02-08       Impact factor: 6.150

8.  Protease-activated receptor-2 signaling through β-arrestin-2 mediates Alternaria alkaline serine protease-induced airway inflammation.

Authors:  Michael C Yee; Heddie L Nichols; Danny Polley; Mahmoud Saifeddine; Kasturi Pal; Kyu Lee; Emma H Wilson; Michael O Daines; Morley D Hollenberg; Scott Boitano; Kathryn A DeFea
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-10-18       Impact factor: 5.464

9.  Airway administration of OM-85, a bacterial lysate, blocks experimental asthma by targeting dendritic cells and the epithelium/IL-33/ILC2 axis.

Authors:  Vadim Pivniouk; Joao A Gimenes-Junior; Peace Ezeh; Ashley Michael; Oksana Pivniouk; Seongmin Hahn; Sydney R VanLinden; Sean P Malone; Amir Abidov; Dayna Anderson; Justyna Gozdz; Avery DeVries; Fernando D Martinez; Christian Pasquali; Donata Vercelli
Journal:  J Allergy Clin Immunol       Date:  2021-09-22       Impact factor: 10.793

10.  Memory-type ST2+CD4+ T cells participate in the steroid-resistant pathology of eosinophilic pneumonia.

Authors:  Naoko Mato; Kiyoshi Hirahara; Tomomi Ichikawa; Jin Kumagai; Masayuki Nakayama; Hideaki Yamasawa; Masashi Bando; Koichi Hagiwara; Yukihiko Sugiyama; Toshinori Nakayama
Journal:  Sci Rep       Date:  2017-07-28       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.